ALK and non-small cell lung carcinoma: The recently reported ASCEND-4 study (208) compared ceritinib with chemotherapy for treatment-naive patients with advanced ALK-positive NSCLC; this trial allowed both untreated as well as symptomatic BM to be accrued.